Bevacizumab ELISA Kit (Avastin®) (ab237642)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Overview
-
Product name
Bevacizumab ELISA Kit (Avastin®)
See all Bevacizumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall Inter-assay Sample n Mean SD CV% Overall -
Sample type
Serum, Plasma -
Assay type
Quantitative -
Sensitivity
30 ng/ml -
Range
30 ng/ml - 1000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 70% - 130% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Bevacizumab ELISA Kit (Avastin®) (ab237642) is a highly specific and sensitive kit designed for the in vitro determination of Bevacizumab in biological matrices such as human serum and plasma. The density of color is proportional to the amount of Bevacizumab captured from the samples and can be quantified when compared with standard curve.
Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature tha t the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Assay Buffer 2 x 50ml Bevacizumab Standard S1 1 x 300µl Bevacizumab Standard S2 1 x 300µl Bevacizumab Standard S3 1 x 300µl Bevacizumab Standard S4 1 x 300µl Bevacizumab Standard S5 1 x 300µl Bevacizumab Standard S6 1 x 300µl Bevacizumab Standard S7 1 x 300µl HRP-conjugate Probe 1 x 12ml Micro ELISA Plate 1 unit Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash Buffer (20X) 1 x 50ml -
Relevance
Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
Images
-
Example of Bevacizumab standard curve
Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.
